

In a letter to GAO, Reps. Waxman, Dingell, and Stupak ask GAO to examine FDA's monitoring of potential safety issues associated with dietary supplements; FDA's authority to take action in instances where a supplement poses potential safety risks; and FDA's oversight of dietary supplement labels and claims made by dietary supplement manufacturers. **Documents and Links**

- [Letter to GAO](#)